Tranzyme

About:

Tranzyme Pharma is a biopharmaceutical company focused on the discovery, development, and commercialization of mechanism-based therapies.

Website: http://www.tranzyme.com

Top Investors: H.I.G. Capital, Fonds de solidarité FTQ, BDC Venture Capital, Desjardins Venture Capital, Thomas, McNerney & Partners

Description:

Tranzyme Pharma is a biopharmaceutical company focused on the discovery, development, and commercialization of mechanism-based therapies. The company currently has programs for gastrointestinal motility disorders and retains worldwide rights for these programs. The company’s product portfolio includes, TZP-101, for the treatment of post-operative ileus and severe gastroparesis; and TZP-301, for the treatment of obesity and metabolic syndrome. Tranzyme Pharma is based in North Carolina, United States.

Total Funding Amount:

$20M

Estimated Revenue Range:

$1M to $10M

Headquarters Location:

Durham, North Carolina, United States

Founded Date:

1998-01-01

Founders:

Number of Employees:

11-50

Last Funding Date:

2007-11-01

IPO Status:

Private

Industries:

© 2025 bioDAO.ai